However, in spite of these difficulties, immune checkpoint blockade (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4), designed to amplify endogenous anti-tumour T-cell responses, has revolutionised cancer treatment [42,43]. Here, CD274 is linked to neoplasm.